日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial

P024:基线代谢肿瘤体积对早期预后良好的霍奇金淋巴瘤的预测价值——来自前瞻性、多中心 III 期 HD16 试验的数据

Rossetti, Sára; Juul, Sidsel Jacobsen; Eriksson, Frank; Warming, Peder Emil; Glinge, Charlotte; El-Galaly, Tarec Christoffer; Christensen, Jacob Haaber; Kamper, Peter; De Nully Brown, Peter; Maraldo, Maja Vestmø; Tfelt-Hansen, Jacob; Hutchings, Martin; Entrop, Joshua P; Weibull, Caroline E; Smedby, Karin E; Jakobsen, Lasse Hjort; øvlisen, Andreas K; Molin, Daniel; Glimelius, Ingrid; Marklund, Anna; Holte, Harald; Fosså, Alexander; Smeland, Knut B; El-Galaly, Tarec Christoffer; Eloranta, Sandra; Van Heek, Lutz; Stuka, Colin; Kaul, Helen; Müller, Horst; Mettler, Jasmin; Hitz, Felicitas; Baues, Christian; Fuchs, Michael; Borchmann, Peter; Engert, Andreas; Dietlein, Markus; Voltin, Conrad-Amadeus; Kobe, Carsten

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial

基线代谢肿瘤体积对早期预后良好型霍奇金淋巴瘤的预测价值——来自前瞻性、多中心 III 期 HD16 试验的数据

van Heek, Lutz; Stuka, Colin; Kaul, Helen; Müller, Horst; Mettler, Jasmin; Hitz, Felicitas; Baues, Christian; Fuchs, Michael; Borchmann, Peter; Engert, Andreas; Dietlein, Markus; Voltin, Conrad-Amadeus; Kobe, Carsten

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

利妥昔单抗与米托蒽醌:比较晚期复发型多发性硬化症的疗效和安全性

Zrzavy, Tobias; Daniels, Esther; Stuka, Niklas; Weber, Dennis; Winkelmann, Alexander; Rauschka, Helmut; Hecker, Michael; Aboulenein-Djamshidian, Fahmy; Meister, Stefanie; Leutmezer, Fritz; Berger, Thomas; Bsteh, Gabriel; Zettl, Uwe Klaus; Rommer, Paulus

Factors affecting the antigenicity of Trichophyton rubrum

影响红色毛癣菌抗原性的因素

Stuka, A J; Burrell, R